BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17416455)

  • 1. Re: Fabio CalabrĂ² and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26.
    Di Lorenzo G; Autorino R
    Eur Urol; 2007 Aug; 52(2):613-4. PubMed ID: 17416455
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
    Beardsley EK; Chi KN
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):161-6. PubMed ID: 18685415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy in prostate cancer: an update.
    Sartor O
    Clin Genitourin Cancer; 2007 Jun; 5(5):304-5. PubMed ID: 17645826
    [No Abstract]   [Full Text] [Related]  

  • 4. Current chemotherapeutic approaches for androgen-independent prostate cancer.
    Rumohr JA; Chang SS
    Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy with mitoxantrone in hormone-refractory prostate cancer.
    Denes AE
    J Clin Oncol; 1997 Jan; 15(1):410-1. PubMed ID: 8996172
    [No Abstract]   [Full Text] [Related]  

  • 6. Castration-refractory prostate cancer: new therapies, new questions.
    Appleman LJ
    Oncology (Williston Park); 2010 Dec; 24(14):1318-9, 1326. PubMed ID: 21294476
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Axel Heidenreich, David Pfister. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol 2012;62:1201-4.
    Brookman-May S; Tombal B; Joniau S
    Eur Urol; 2013 Sep; 64(3):e62-4. PubMed ID: 23582882
    [No Abstract]   [Full Text] [Related]  

  • 8. Current indications for chemotherapy in prostate cancer patients.
    CalabrĂ² F; Sternberg CN
    Eur Urol; 2007 Jan; 51(1):17-26. PubMed ID: 17007996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Berry WR
    Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based study of prostate cancer chemotherapy.
    Harris V; Lloyd K; Forsey S; Rogers P; Roche M; Parker C
    Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):706-8. PubMed ID: 21602036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing perspectives of the role of chemotherapy in advanced prostate cancer.
    Burgess EF; Roth BJ
    Urol Clin North Am; 2006 May; 33(2):227-36, vii. PubMed ID: 16631461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
    Aktuelle Urol; 2005 Sep; 36(5):385-7. PubMed ID: 16163602
    [No Abstract]   [Full Text] [Related]  

  • 13. Name that prostate cancer drug.
    Gomella LG
    Can J Urol; 2011 Jun; 18(3):5666. PubMed ID: 21703036
    [No Abstract]   [Full Text] [Related]  

  • 14. New drugs: Sipuleucel-T, cabazitaxel, and collagenase clostridium histolyticum.
    Hussar DA; Daniels WL
    J Am Pharm Assoc (2003); 2010; 50(6):772-5. PubMed ID: 21071329
    [No Abstract]   [Full Text] [Related]  

  • 15. Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer.
    Dreicer R
    Urol Oncol; 2008; 26(4):426-9. PubMed ID: 18593622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising novel cytotoxic agents and combinations in metastatic prostate cancer.
    Bradley DA; Hussain M
    Cancer J; 2008; 14(1):15-9. PubMed ID: 18303478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successive therapies may extend survival in AIPC. Interview by Alice Goodman.
    Petrylak D
    RN; 2007 Mar; 70(3):1-2. PubMed ID: 17405359
    [No Abstract]   [Full Text] [Related]  

  • 18. Highlights from the XII European Cancer Conference Copenhagen, Denmark.
    Tyagi P; Price N; Reddy K; Klem J
    Clin Prostate Cancer; 2003 Dec; 2(3):137-41. PubMed ID: 15040855
    [No Abstract]   [Full Text] [Related]  

  • 19. [Chemotherapy for prostate cancer].
    Itoh N
    Nihon Rinsho; 2005 Feb; 63(2):293-7. PubMed ID: 15714981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Special report: treatments for castration-resistant metastatic prostate cancer.
    BlueCross BlueShield Association
    Technol Eval Cent Assess Program Exec Summ; 2013 Apr; 27(7):1-4. PubMed ID: 23865104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.